 |
| |
| Jul-12-18 | Initiated |
Seaport Global Securities |
Buy |
$30 |
|
| Mar-23-18 | Downgrade |
Wedbush |
Outperform → Neutral |
$47 → $19 |
|
| Mar-05-18 | Downgrade |
Needham |
Buy → Hold |
|
|
| Nov-08-17 | Initiated |
H.C. Wainwright |
Buy |
$30 |
|
| May-11-17 | Downgrade |
Cantor Fitzgerald |
Buy → Neutral |
$21 → $15 |
|
| Mar-17-17 | Reiterated |
Needham |
Buy |
$24 → $22 |
|
| Mar-17-17 | Reiterated |
Maxim Group |
Buy |
$19 → $22 |
|
| Nov-16-16 | Reiterated |
Wedbush |
Outperform |
$56 → $47 |
|
| Nov-10-16 | Reiterated |
Needham |
Buy |
$28 → $24 |
|
| Aug-10-16 | Reiterated |
Maxim Group |
Buy |
$30 → $19 |
|
| Jun-03-16 | Initiated |
Cantor Fitzgerald |
Buy |
$21 |
|
| Mar-02-16 | Reiterated |
Needham |
Buy |
$30 → $28 |
|
| Feb-29-16 | Reiterated |
Wedbush |
Outperform |
$65 → $62 |
|
| Nov-11-15 | Reiterated |
Needham |
Buy |
$32 → $30 |
|
| Aug-18-15 | Reiterated |
WBB Securities |
Strong Buy |
$60 → $75 |
|
| Aug-10-15 | Initiated |
ROTH Capital |
Buy |
$38 |
|
| Mar-18-15 | Reiterated |
Needham |
Buy |
$22 → $32 |
|
| Feb-20-15 | Reiterated |
Maxim Group |
Buy |
$28 → $30 |
|
| Feb-18-15 | Reiterated |
MLV & Co |
Buy |
$19 → $38 |
|
| Nov-13-14 | Reiterated |
Maxim Group |
Buy |
$20 → $28 |
|
|
|
| Feb-14-19 03:40PM | Why Omeros Stock Jumped Today Motley Fool +9.63% |
| 08:30AM | Omeros Corporation Streamlines Path to Biologics License Application for OMS721 in HSCT-TMA Following Meeting with FDA Business Wire |
| Feb-12-19 08:30AM | Omeros Corporation Appoints Thomas F. Bumol, Ph.D., to Board of Directors Business Wire |
| Jan-30-19 11:14AM | Can We See Significant Insider Ownership On The Omeros Corporation (NASDAQ:OMER) Share Register? Simply Wall St. |
| Jan-17-19 11:11AM | Omeros Finalizes Clinical Plan For Kidney Disease Treatment, Reports Additional Positive Phase 2 Data Benzinga |
| 08:15AM | Omeros Finalizes with FDA Clinical Plan for OMS721 Approval in IgA Nephropathy Business Wire |
| Jan-14-19 07:30AM | Omeros Corporation Announces Record High Quarterly Revenue Results for the Fourth Quarter 2018 Business Wire |
| Jan-03-19 07:35AM | Investor Expectations to Drive Momentum within L3 Technologies, The Goldman Sachs Group, Genuine Parts, Bruker, Omeros, and Aimmune Therapeutics Discovering Underlying Factors of Influence GlobeNewswire |
| Dec-20-18 08:30AM | Omeros Establishes Independent Academic Leadership Committee for its OMS721 Phase 3 Clinical Program in IgA Nephropathy Business Wire |
| Dec-11-18 07:30AM | Omeros Announces Research Collaboration with University of Cambridge Business Wire |
| Dec-06-18 08:30AM | Omeros Announces Clinical Strategy to Accelerate Pediatric Development of OMS721 for the Treatment of Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (HSCT-TMA) Business Wire |
| Dec-03-18 08:30AM | Omeros Announces Additions to Senior Management Team Business Wire |
| 08:14AM | Edited Transcript of OMER earnings conference call or presentation 9-Nov-18 1:30pm GMT Thomson Reuters StreetEvents |
| Nov-30-18 08:25AM | New Research Coverage Highlights Omeros, Apple, Bio-Rad Laboratories, Cott, Darling Ingredients, and Osisko Gold Royalties Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire |
| Nov-29-18 11:12AM | Does Omeros Corporations (NASDAQ:OMER) CEO Salary Reflect Performance? Simply Wall St. |
| Nov-09-18 12:12PM | Here's Why Omeros Corporation Fell as Much as 24.5% Today Motley Fool -18.73% |
| 07:32AM | The Daily Biotech Pulse: SITC Presentations Pick Up Pace, Sandoz' Voluntary Recall Benzinga |
| 07:00AM | Omeros Announces Pricing of $210 Million Offering of Convertible Senior Notes Due 2023 Business Wire |
| 06:55AM | Today's Research Reports on Trending Tickers: Omeros and Spectrum Pharmaceuticals ACCESSWIRE |
| Nov-08-18 05:45PM | Omeros (OMER) Reports Q3 Loss, Tops Revenue Estimates Zacks |
| 04:41PM | Omeros: 3Q Earnings Snapshot Associated Press |
| 04:26PM | Omeros Announces Proposed $210 Million Offering of Convertible Senior Notes Due 2023 PR Newswire |
| 04:02PM | Omeros Corporation Reports Third Quarter 2018 Financial Results Business Wire |
| Nov-05-18 07:00AM | Omeros Corporation to Announce Third Quarter 2018 Financial Results on November 9, 2018 Business Wire |
| Nov-03-18 12:24PM | Why Omeros Corporation Fell 37.4% in October Motley Fool |
| Oct-23-18 08:30AM | FDA Grants Orphan Drug Designation to Omeros OMS721 for Treatment of Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy Business Wire |
| 07:30AM | New Research: Key Drivers of Growth for Hecla Mining, Atlas Air Worldwide, Encana, Omeros, Lowe's Companies, and Oaktree Specialty Lending Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire |
| Oct-08-18 11:15AM | Are These Beaten-Down Clinical-Stage Biotech Stocks Buys? Motley Fool +5.51% |
| Oct-02-18 03:32PM | Why Omeros Corporation Stock Is Bouncing Back Today Motley Fool +10.24% |
| 08:00AM | Today's Research Reports on Trending Tickers: Omeros and Sarepta Therapeutics ACCESSWIRE |
| Oct-01-18 03:15PM | Omeros stock drops 45% after kidney disease trial results MarketWatch -42.81% |
| 02:15PM | Omeros Corporation Announces Additional Positive Data for OMS721 in IgA Nephropathy Business Wire |
| 08:45AM | Omeros Corporation Announces Reinstatement of Pass-Through Status for OMIDRIA® Business Wire |
| Sep-28-18 07:37AM | Best ETFs for 2018: Dont Sweat This Quarter for the SBIO ETF InvestorPlace |
| Sep-27-18 07:00AM | Omeros to Present at the 2018 Cantor Global Healthcare Conference Business Wire |
| Sep-12-18 10:18AM | Jim Cramer Shares Thoughts On Skyworks Solutions, Cypress Semiconductor, More Benzinga |
| Sep-11-18 06:57PM | Cramer's lightning round: Don't block the 'freight train' that is Skyworks Solutions' stock CNBC |
| Sep-07-18 07:00AM | Omeros to Present at the Morgan Stanley Global Healthcare Conference Business Wire |
| Sep-05-18 09:23AM | 3 Biotech Stocks That Still Have Major Catalysts in September Motley Fool |
| Sep-04-18 04:11PM | Edited Transcript of OMER earnings conference call or presentation 9-Aug-18 8:30pm GMT Thomson Reuters StreetEvents |
| Aug-28-18 07:55AM | Detailed Research: Economic Perspectives on Allegheny Technologies, Ring Energy, Aerohive Networks, Omeros, Adtalem Global Education, and BioPharmX What Drives Growth in Today's Competitive Landscape GlobeNewswire |
| 07:30AM | European Commission Designates OMS721 as an Orphan Medicinal Product for Treatment in Hematopoietic Stem Cell Transplantation Business Wire |
| Aug-10-18 08:00AM | Today's Research Reports on Trending Tickers: Omeros and Intrexon ACCESSWIRE -18.29% |
| 07:00AM | Omeros to Present at the 2018 Wedbush PacGrow Healthcare Conference Business Wire |
| Aug-09-18 05:45PM | Omeros (OMER) Reports Q2 Loss, Misses Revenue Estimates Zacks |
| 04:37PM | Omeros: 2Q Earnings Snapshot Associated Press |
| 04:02PM | Omeros Corporation Reports Second Quarter 2018 Financial Results Business Wire |
| Aug-03-18 07:00AM | Omeros Corporation to Announce Second Quarter 2018 Financial Results on August 9, 2018 Business Wire |
| Aug-02-18 07:00AM | Omeros Hires Former Sanofi Global Development Head as Chief Medical Officer Business Wire |
| Jul-26-18 07:30AM | Sandoz Amends ANDA to Not Seek Approval for Generic Version of OMIDRIA Until Patents for Omeros Drug Expire Business Wire |
| Jul-25-18 08:30AM | Omeros OMS721 Receives European Orphan Drug Designation Positive Opinion for Treatment in Hematopoietic Stem Cell Transplantation Business Wire +5.30% |
| Jul-23-18 07:15AM | Omeros Corporation Initiates Sales of OMIDRIA® in Europe Business Wire +7.79% |
| Jul-17-18 07:00AM | Omeros Initiates Dosing in Phase 1 Clinical Trial for OMS527 Targeting Addiction Business Wire |
| Jul-13-18 07:40AM | Complimentary Technical Snapshots on OHR Pharma and Three More Biotech Stocks ACCESSWIRE |
| Jun-27-18 09:15AM | Omeros Obtains Approval to Initiate Phase 1 Clinical Trial for its OMS527 Addiction Treatment Business Wire |
| Jun-26-18 07:45AM | Analysis: Positioning to Benefit within The Manitowoc, Omeros, Catabasis Pharmaceuticals, Zayo Group, Covanta Holding, and Seattle Genetics Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire |
| Jun-21-18 08:00AM | Report: Developing Opportunities within ABIOMED, Avid Technology, Unit, Omeros, Strayer Education, and NeoGenomics Future Expectations, Projections Moving into 2018 GlobeNewswire -5.29% |
| Jun-12-18 08:05AM | Breakfast Technical Briefing on Omeros and Three Other Additional Biotech Stocks ACCESSWIRE |
| May-29-18 07:10AM | Wired News Omeros Settles Lawsuit Against Lupin for Filing ANDA With FDA for Marketing Generic Version of OMIDRIA(R) ACCESSWIRE |
| May-24-18 07:00AM | Omeros Announces Settlement of Infringement Suit Against ANDA Filer Lupin Business Wire |
| May-16-18 04:40PM | Why Omeros, Party City Holdco, and Overstock.com Slumped Today Motley Fool -18.13% |
| May-15-18 05:51AM | Edited Transcript of OMER earnings conference call or presentation 10-May-18 8:30pm GMT Thomson Reuters StreetEvents +7.81% |
| May-14-18 08:00AM | Today's Research Reports on Trending Tickers: Omeros and bluebird bio ACCESSWIRE +13.98% |
| May-11-18 01:29PM | Here's Why Omeros Corporation Stock Is Surging Today Motley Fool +23.31% |
| 08:00AM | Today's Research Reports on Trending Tickers: BioMarin Pharmaceutical and Omeros Corporation ACCESSWIRE |
| May-10-18 05:26PM | Omeros: 1Q Earnings Snapshot Associated Press |
| 04:05PM | Omeros Corporation Reports First Quarter 2018 Financial Results Business Wire |
| May-07-18 10:00AM | Omeros Corporation to Announce First Quarter 2018 Financial Results on May 10, 2018 Business Wire |
| Apr-26-18 02:15PM | FDA Grants Breakthrough Therapy Designation to Omeros MASP-2 Inhibitor OMS721 for the Treatment of High-Risk Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy Business Wire +8.02% |
| Apr-19-18 07:35AM | Research Report Identifies T. Rowe Price Group, Omeros, Old Dominion Freight Line, Dillard's, BGC Partners, and Rexnord with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire |
| 07:00AM | Additional Clinical Studies Supporting the Benefits of OMIDRIA® Presented at the American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting Business Wire |
| Apr-13-18 09:10AM | Omeros Corporation Announces Upcoming Presentations of New Data on OMIDRIA® at the American Society of Cataract and Refractive Surgery Meeting Business Wire -5.59% |
| Apr-12-18 09:10AM | OMIDRIA® Added to Veterans Health Administration National Formulary Business Wire |
| Apr-11-18 09:15AM | Omeros Announces Amendment of Credit Facility Business Wire +9.64% |
| Apr-04-18 09:51AM | What Should Investors Know About Omeros Corporations (NASDAQ:OMER) Growth? Simply Wall St. +11.03% |
| Mar-26-18 12:33PM | Omeros, Mattel, And 3 Other Stocks In Clear Trending Patterns This Week Benzinga -12.88% |
| Mar-23-18 06:56AM | ICYMI: GameStop, Omeros, Congress Impacts Biotechs Benzinga -10.54% |
| Mar-22-18 05:28PM | New Budget Deals Big Pharma a Blow on Medicare Part D, but Omeros Scores TheStreet.com +35.31% |
| 04:31PM | Why Lands' End, Omeros, and MGP Ingredients Jumped Today Motley Fool |
| 03:42PM | Omeros Elevated By Medicare Reimbursement And OMS721 Progress, Says Maxim Benzinga |
| 12:09PM | Here's Why Omeros Corporation Is Bouncing Back Today Motley Fool |
| 11:46AM | Biotech Winners And Losers From Congress' Latest Funding Bill Benzinga |
| 11:34AM | Omeros shares surge 45% on spending bill that benefits its drug MarketWatch |
| 09:18AM | Omeros Corporation (NASDAQ:OMER): Is Breakeven Near? Simply Wall St. |
| 08:39AM | Benzinga Pro's 5 Stocks To Watch Today Benzinga |
| Mar-05-18 08:17AM | Is Omeros Corporation a Buy on the Dip? Motley Fool |
| Mar-02-18 08:20AM | Todays Research Reports on Trending Tickers: Omeros and Opko Health ACCESSWIRE |
| 08:06AM | Edited Transcript of OMER earnings conference call or presentation 1-Mar-18 9:30pm GMT Thomson Reuters StreetEvents |
| Mar-01-18 04:53PM | Omeros reports 4Q loss Associated Press |
| 04:02PM | Omeros Corporation Reports Fourth Quarter and Year-End 2017 Financial Results Business Wire |
| 12:30PM | Omeros Corporation to Host Earnings Call ACCESSWIRE |
| Feb-26-18 09:30AM | Omeros Corporation to Announce Fourth Quarter and Year-End 2017 Financial Results on March 1, 2018 Business Wire +10.60% |
| Feb-15-18 07:42AM | Omeros Reports Significant Improvement in Overall Survival Data in OMS721-Treated Patients with Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy Business Wire |
| Feb-14-18 04:33PM | Why Biogen, Groupon, and Omeros Slumped Today Motley Fool -17.58% |
| 03:54PM | The Report that Sent Omeros Corporation (OMER) Shares Tumbling SmarterAnalyst |
| 01:27PM | Here's Why Omeros Corporation Is Getting Beaten Down on Wednesday Motley Fool |
| 09:00AM | Short Seller Who Predicted Plunge in Flotek Has a New Target Bloomberg |
| Feb-09-18 07:40AM | Report: Exploring Fundamental Drivers Behind Bank of Hawaii, Omeros, OneMain, Veritex, Versum Materials, and SiteOne Landscape Supply New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire |
| Jan-22-18 07:00AM | European Medicines Agency Issues Orphan Drug Designation Positive Opinion for Omeros OMS721 in the Treatment of IgA Nephropathy Business Wire |
| Jan-11-18 03:00AM | Omeros Scores Relative Strength Rating Upgrade; Hits Key Threshold Investor's Business Daily |
|
|
|
|
| Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company markets OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States. Its clinical programs include OMS721 that is in Phase III clinical trial for treating immunoglobulin A (IgA) nephropathy, hematopoietic stem cell transplant-associated thrombotic microangiopathy (HCT-TMA), and atypical hemolytic uremic syndrome (aHUS); and in Phase II clinical trial to treat IgA nephropathy, membranous nephropathy, lupus nephritis, and complement component glomerulopathy. The company's clinical programs also consists of OMS824, which is in Phase II clinical trial for treating Huntington's diseases and schizophrenia; and OMS405 that is in Phase II clinical trial to treat opioids, nicotine, and alcohol addiction. Its preclinical programs comprise OMS527 for the treatment of addiction and compulsive disorders, as well as for movement disorders; and OMS906 to treat paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders. The company's preclinical programs also include MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HCT-TMA, and age-related macular degeneration; MASP-3-small-molecule inhibitors used for the treatment of PNH and other alternative pathway disorders; G protein-coupled receptor (GPCR) platform, including GPR174 and other Class A orphan GPCRS for treating CNS, metabolic, CV, oncologic, musculoskeletal, and other disorders; and antibody platform for metabolic, CV, oncologic, musculoskeletal and other disorders. Omeros Corporation was incorporated in 1994 and is based in Seattle, Washington. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Kelbon Marcia S. | VP Patent and General Counsel | Aug 31 | Option Exercise | 5.10 | 15,529 | 79,269 | 200,645 | Aug 31 09:32 PM | | Kelbon Marcia S. | VP Patent and General Counsel | Aug 31 | Sale | 25.75 | 7,529 | 193,846 | 192,645 | Aug 31 09:32 PM | | Kelbon Marcia S. | VP Patent and General Counsel | Aug 30 | Option Exercise | 4.10 | 35,000 | 143,500 | 227,645 | Aug 31 09:32 PM | | Kelbon Marcia S. | VP Patent and General Counsel | Aug 30 | Sale | 24.45 | 35,000 | 855,750 | 192,645 | Aug 31 09:32 PM | | Kelbon Marcia S. | VP Patent and General Counsel | Jul 27 | Option Exercise | 4.10 | 5,723 | 23,464 | 198,368 | Jul 30 07:00 PM | | Kelbon Marcia S. | VP Patent and General Counsel | Jul 27 | Sale | 21.73 | 5,723 | 124,357 | 192,645 | Jul 30 07:00 PM | | Kelbon Marcia S. | VP Patent and General Counsel | Jul 26 | Option Exercise | 4.46 | 43,000 | 191,900 | 219,645 | Jul 30 07:00 PM | | Kelbon Marcia S. | VP Patent and General Counsel | Jul 26 | Sale | 21.53 | 35,000 | 753,687 | 184,645 | Jul 30 07:00 PM | | Kelbon Marcia S. | VP Patent and General Counsel | Jul 12 | Option Exercise | 4.10 | 4,277 | 17,536 | 188,922 | Jul 13 08:00 PM | | Kelbon Marcia S. | VP Patent and General Counsel | Jul 12 | Sale | 21.48 | 4,277 | 91,886 | 184,645 | Jul 13 08:00 PM | | JACOBSEN MICHAEL A | VP Finance and CAO | May 15 | Option Exercise | 9.37 | 17,812 | 166,898 | 21,312 | May 16 06:00 PM | | JACOBSEN MICHAEL A | VP Finance and CAO | May 15 | Sale | 24.95 | 12,812 | 319,659 | 8,500 | May 16 06:00 PM | | JACOBSEN MICHAEL A | VP Finance and CAO | May 14 | Option Exercise | 9.37 | 10,980 | 102,883 | 19,480 | May 16 06:00 PM | | JACOBSEN MICHAEL A | VP Finance and CAO | May 14 | Sale | 22.45 | 10,980 | 246,501 | 8,500 | May 16 06:00 PM |
|
|
|
|
|
|
